Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study.
Few studies have evaluated the chemopreventive effect of aspirin on the cancer risk in elderly women. We examined associations between frequency, dose, and duration of aspirin use with incidence of 719 aspirin-sensitive cancers (cancers of colon, pancreas, breast, and ovaries) in the Iowa Women's Health Study (IWHS), a prospective cohort of women over 70 years old.



Aspirin frequency, dose, and duration were self-reported in the 2004 IWHS questionnaire. Women were followed-up to 2011. Cancer cases were ascertained by linkage to the Iowa State Health Registry. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CI).



Among the 14,386 women, 30 % were nonusers of aspirin; 34 % used low-dose aspirin, and 36 % used regular- or high-dose aspirin. Compared with nonuse of aspirin, the HRs (95 % CI) for incidence of aspirin-sensitive cancers were 0.87 (0.72-1.06) for regular to high doses of aspirin use, 0.95 (0.80-1.13) for aspirin use 6+ times per week, and 0.93 (0.74-1.17) for aspirin use for 10+ years. For cumulative aspirin use, HR (95 % CI) was 0.87 (0.70-1.09) for >60,000 mg of aspirin per year and 0.95 (0.75-1.21) for >280,000 mg of aspirin in their lifetime, versus nonuse of aspirin. Results were similar for the all-cause cancer death as an endpoint, with a significant inverse association observed between lifetime aspirin dose and cancer mortality [<95,000 mg vs nonuser HR 0.76 (0.61-0.95)].



These findings suggest that aspirin use may prevent incident breast, colon, pancreatic, and ovarian cancer in elderly women.
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Lisa E
LE
Vaughan
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S. 2nd Street Suite 300, Minneapolis, MN, USA.|Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Anna
A
Prizment
Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.|University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
Cindy K
CK
Blair
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
William
W
Thomas
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S. 2nd Street Suite 300, Minneapolis, MN, USA. ander116@umn.edu.|Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. ander116@umn.edu.
Kristin E
KE
Anderson
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology*; D003110:Colonic Neoplasms / Q000453:epidemiology*; D005260:Female; D006801:Humans; D015994:Incidence; D007484:Iowa / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000453:epidemiology*; D010190:Pancreatic Neoplasms / Q000453:epidemiology*; D011446:Prospective Studies; D065840:Protective Factors; D012306:Risk; D016387:Women's Health
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D001241:Aspirin
Aspirin; Cancer; Cohort; Elderly; NSAIDs; Women
Ann Oncol. 2012 Jun;23(6):1403-15
22517822
Nat Rev Clin Oncol. 2012 Apr 03;9(5):259-67
22473097
J Natl Cancer Inst. 2014 Feb;106(2):djt431
24503200
Lancet Oncol. 2009 May;10(5):501-7
19410194
Cancer Discov. 2013 Dec;3(12):1324
24327682
Cancer. 2012 Mar 1;118(5):1371-86
21953606
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):435-42
20142241
Lancet. 2011 Jan 1;377(9759):31-41
21144578
Int J Cancer. 2003 Sep 20;106(5):784-8
12866040
JAMA Oncol. 2016 Jun 1;2(6):762-9
26940135
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):792-802
23462914
Sci Rep. 2015 Oct 21;5:15460
26486090
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1785-90
17035383
Circulation. 2006 Feb 14;113(6):e85-151
16407573
Acta Obstet Gynecol Scand. 2013 Mar;92(3):245-55
23240575
J Natl Cancer Inst. 2002 Aug 7;94(15):1168-71
12165642
Breast Cancer Res Treat. 2011 Feb;126(1):149-55
20669045
N Engl J Med. 1999 Dec 30;341(27):2061-7
10615079
Ann Intern Med. 2016 Jun 21;164(12):814-25
27064482
Lancet. 2012 Apr 28;379(9826):1602-12
22440946
Mayo Clin Proc. 2016 Jan;91(1):71-80
26678006
Lancet. 2011 Jan 1;377(9759):3-4
21195237
Lancet Oncol. 2012 May;13(5):518-27
22440112
J Natl Cancer Inst. 2007 Jun 6;99(11):881-9
17551148
Cancer. 2009 Sep 15;115(18 Suppl):4283-97
19731348
Ann Intern Med. 2013 Nov 19;159(10):667-76
24247672
Contemp Clin Trials. 2013 Nov;36(2):555-64
24113028
Cancer. 1995 Jul 15;76(2):275-83
8625103
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91
12496048
Am J Epidemiol. 1994 May 15;139(10):990-1000
8178787